Global Inactivated Influenza Vaccine Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “Inactivated Influenza Vaccine Industry Forecast” looks at past sales and reviews total world Inactivated Influenza Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Inactivated Influenza Vaccine sales for 2023 through 2029. With Inactivated Influenza Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Inactivated Influenza Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Inactivated Influenza Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Inactivated Influenza Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Inactivated Influenza Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Inactivated Influenza Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Inactivated Influenza Vaccine.
The global Inactivated Influenza Vaccine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Inactivated Influenza Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Inactivated Influenza Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Inactivated Influenza Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Inactivated Influenza Vaccine players cover CSL Limited, GSK, Sanofi Pasteur, Viatris, Hualan Biological, AstraZeneca, Sinovac Biotech, Aleph Biomedical and Abbott Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Inactivated Influenza Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Inactivated Influenza Vaccine market?
What factors are driving Inactivated Influenza Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Inactivated Influenza Vaccine market opportunities vary by end market size?
How does Inactivated Influenza Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Inactivated Influenza Vaccine Industry Forecast” looks at past sales and reviews total world Inactivated Influenza Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Inactivated Influenza Vaccine sales for 2023 through 2029. With Inactivated Influenza Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Inactivated Influenza Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Inactivated Influenza Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Inactivated Influenza Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Inactivated Influenza Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Inactivated Influenza Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Inactivated Influenza Vaccine.
The global Inactivated Influenza Vaccine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Inactivated Influenza Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Inactivated Influenza Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Inactivated Influenza Vaccine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Inactivated Influenza Vaccine players cover CSL Limited, GSK, Sanofi Pasteur, Viatris, Hualan Biological, AstraZeneca, Sinovac Biotech, Aleph Biomedical and Abbott Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Inactivated Influenza Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Trivalent Influenza Vaccine
- Quadrivalent Influenza Vaccine
- Children
- Adolescence
- Adults
- Elderly
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- CSL Limited
- GSK
- Sanofi Pasteur
- Viatris
- Hualan Biological
- AstraZeneca
- Sinovac Biotech
- Aleph Biomedical
- Abbott Laboratories
- Novartis International
What is the 10-year outlook for the global Inactivated Influenza Vaccine market?
What factors are driving Inactivated Influenza Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Inactivated Influenza Vaccine market opportunities vary by end market size?
How does Inactivated Influenza Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Inactivated Influenza Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Inactivated Influenza Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Inactivated Influenza Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Inactivated Influenza Vaccine Segment by Type
2.2.1 Trivalent Influenza Vaccine
2.2.2 Quadrivalent Influenza Vaccine
2.3 Inactivated Influenza Vaccine Sales by Type
2.3.1 Global Inactivated Influenza Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Inactivated Influenza Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Inactivated Influenza Vaccine Sale Price by Type (2018-2023)
2.4 Inactivated Influenza Vaccine Segment by Application
2.4.1 Children
2.4.2 Adolescence
2.4.3 Adults
2.4.4 Elderly
2.5 Inactivated Influenza Vaccine Sales by Application
2.5.1 Global Inactivated Influenza Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Inactivated Influenza Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Inactivated Influenza Vaccine Sale Price by Application (2018-2023)
3 GLOBAL INACTIVATED INFLUENZA VACCINE BY COMPANY
3.1 Global Inactivated Influenza Vaccine Breakdown Data by Company
3.1.1 Global Inactivated Influenza Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Inactivated Influenza Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Inactivated Influenza Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Inactivated Influenza Vaccine Revenue by Company (2018-2023)
3.2.2 Global Inactivated Influenza Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Inactivated Influenza Vaccine Sale Price by Company
3.4 Key Manufacturers Inactivated Influenza Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Inactivated Influenza Vaccine Product Location Distribution
3.4.2 Players Inactivated Influenza Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR INACTIVATED INFLUENZA VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Inactivated Influenza Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Inactivated Influenza Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Inactivated Influenza Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Inactivated Influenza Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Inactivated Influenza Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Inactivated Influenza Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Inactivated Influenza Vaccine Sales Growth
4.4 APAC Inactivated Influenza Vaccine Sales Growth
4.5 Europe Inactivated Influenza Vaccine Sales Growth
4.6 Middle East & Africa Inactivated Influenza Vaccine Sales Growth
5 AMERICAS
5.1 Americas Inactivated Influenza Vaccine Sales by Country
5.1.1 Americas Inactivated Influenza Vaccine Sales by Country (2018-2023)
5.1.2 Americas Inactivated Influenza Vaccine Revenue by Country (2018-2023)
5.2 Americas Inactivated Influenza Vaccine Sales by Type
5.3 Americas Inactivated Influenza Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Inactivated Influenza Vaccine Sales by Region
6.1.1 APAC Inactivated Influenza Vaccine Sales by Region (2018-2023)
6.1.2 APAC Inactivated Influenza Vaccine Revenue by Region (2018-2023)
6.2 APAC Inactivated Influenza Vaccine Sales by Type
6.3 APAC Inactivated Influenza Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Inactivated Influenza Vaccine by Country
7.1.1 Europe Inactivated Influenza Vaccine Sales by Country (2018-2023)
7.1.2 Europe Inactivated Influenza Vaccine Revenue by Country (2018-2023)
7.2 Europe Inactivated Influenza Vaccine Sales by Type
7.3 Europe Inactivated Influenza Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Inactivated Influenza Vaccine by Country
8.1.1 Middle East & Africa Inactivated Influenza Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Inactivated Influenza Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Inactivated Influenza Vaccine Sales by Type
8.3 Middle East & Africa Inactivated Influenza Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Inactivated Influenza Vaccine
10.3 Manufacturing Process Analysis of Inactivated Influenza Vaccine
10.4 Industry Chain Structure of Inactivated Influenza Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Inactivated Influenza Vaccine Distributors
11.3 Inactivated Influenza Vaccine Customer
12 WORLD FORECAST REVIEW FOR INACTIVATED INFLUENZA VACCINE BY GEOGRAPHIC REGION
12.1 Global Inactivated Influenza Vaccine Market Size Forecast by Region
12.1.1 Global Inactivated Influenza Vaccine Forecast by Region (2024-2029)
12.1.2 Global Inactivated Influenza Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Inactivated Influenza Vaccine Forecast by Type
12.7 Global Inactivated Influenza Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 CSL Limited
13.1.1 CSL Limited Company Information
13.1.2 CSL Limited Inactivated Influenza Vaccine Product Portfolios and Specifications
13.1.3 CSL Limited Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 CSL Limited Main Business Overview
13.1.5 CSL Limited Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Inactivated Influenza Vaccine Product Portfolios and Specifications
13.2.3 GSK Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Sanofi Pasteur
13.3.1 Sanofi Pasteur Company Information
13.3.2 Sanofi Pasteur Inactivated Influenza Vaccine Product Portfolios and Specifications
13.3.3 Sanofi Pasteur Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Pasteur Main Business Overview
13.3.5 Sanofi Pasteur Latest Developments
13.4 Viatris
13.4.1 Viatris Company Information
13.4.2 Viatris Inactivated Influenza Vaccine Product Portfolios and Specifications
13.4.3 Viatris Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Viatris Main Business Overview
13.4.5 Viatris Latest Developments
13.5 Hualan Biological
13.5.1 Hualan Biological Company Information
13.5.2 Hualan Biological Inactivated Influenza Vaccine Product Portfolios and Specifications
13.5.3 Hualan Biological Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Hualan Biological Main Business Overview
13.5.5 Hualan Biological Latest Developments
13.6 AstraZeneca
13.6.1 AstraZeneca Company Information
13.6.2 AstraZeneca Inactivated Influenza Vaccine Product Portfolios and Specifications
13.6.3 AstraZeneca Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 AstraZeneca Main Business Overview
13.6.5 AstraZeneca Latest Developments
13.7 Sinovac Biotech
13.7.1 Sinovac Biotech Company Information
13.7.2 Sinovac Biotech Inactivated Influenza Vaccine Product Portfolios and Specifications
13.7.3 Sinovac Biotech Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Sinovac Biotech Main Business Overview
13.7.5 Sinovac Biotech Latest Developments
13.8 Aleph Biomedical
13.8.1 Aleph Biomedical Company Information
13.8.2 Aleph Biomedical Inactivated Influenza Vaccine Product Portfolios and Specifications
13.8.3 Aleph Biomedical Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Aleph Biomedical Main Business Overview
13.8.5 Aleph Biomedical Latest Developments
13.9 Abbott Laboratories
13.9.1 Abbott Laboratories Company Information
13.9.2 Abbott Laboratories Inactivated Influenza Vaccine Product Portfolios and Specifications
13.9.3 Abbott Laboratories Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Abbott Laboratories Main Business Overview
13.9.5 Abbott Laboratories Latest Developments
13.10 Novartis International
13.10.1 Novartis International Company Information
13.10.2 Novartis International Inactivated Influenza Vaccine Product Portfolios and Specifications
13.10.3 Novartis International Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Novartis International Main Business Overview
13.10.5 Novartis International Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Inactivated Influenza Vaccine Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Inactivated Influenza Vaccine by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Inactivated Influenza Vaccine by Country/Region, 2018, 2022 & 2029
2.2 Inactivated Influenza Vaccine Segment by Type
2.2.1 Trivalent Influenza Vaccine
2.2.2 Quadrivalent Influenza Vaccine
2.3 Inactivated Influenza Vaccine Sales by Type
2.3.1 Global Inactivated Influenza Vaccine Sales Market Share by Type (2018-2023)
2.3.2 Global Inactivated Influenza Vaccine Revenue and Market Share by Type (2018-2023)
2.3.3 Global Inactivated Influenza Vaccine Sale Price by Type (2018-2023)
2.4 Inactivated Influenza Vaccine Segment by Application
2.4.1 Children
2.4.2 Adolescence
2.4.3 Adults
2.4.4 Elderly
2.5 Inactivated Influenza Vaccine Sales by Application
2.5.1 Global Inactivated Influenza Vaccine Sale Market Share by Application (2018-2023)
2.5.2 Global Inactivated Influenza Vaccine Revenue and Market Share by Application (2018-2023)
2.5.3 Global Inactivated Influenza Vaccine Sale Price by Application (2018-2023)
3 GLOBAL INACTIVATED INFLUENZA VACCINE BY COMPANY
3.1 Global Inactivated Influenza Vaccine Breakdown Data by Company
3.1.1 Global Inactivated Influenza Vaccine Annual Sales by Company (2018-2023)
3.1.2 Global Inactivated Influenza Vaccine Sales Market Share by Company (2018-2023)
3.2 Global Inactivated Influenza Vaccine Annual Revenue by Company (2018-2023)
3.2.1 Global Inactivated Influenza Vaccine Revenue by Company (2018-2023)
3.2.2 Global Inactivated Influenza Vaccine Revenue Market Share by Company (2018-2023)
3.3 Global Inactivated Influenza Vaccine Sale Price by Company
3.4 Key Manufacturers Inactivated Influenza Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Inactivated Influenza Vaccine Product Location Distribution
3.4.2 Players Inactivated Influenza Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR INACTIVATED INFLUENZA VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Inactivated Influenza Vaccine Market Size by Geographic Region (2018-2023)
4.1.1 Global Inactivated Influenza Vaccine Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Inactivated Influenza Vaccine Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Inactivated Influenza Vaccine Market Size by Country/Region (2018-2023)
4.2.1 Global Inactivated Influenza Vaccine Annual Sales by Country/Region (2018-2023)
4.2.2 Global Inactivated Influenza Vaccine Annual Revenue by Country/Region (2018-2023)
4.3 Americas Inactivated Influenza Vaccine Sales Growth
4.4 APAC Inactivated Influenza Vaccine Sales Growth
4.5 Europe Inactivated Influenza Vaccine Sales Growth
4.6 Middle East & Africa Inactivated Influenza Vaccine Sales Growth
5 AMERICAS
5.1 Americas Inactivated Influenza Vaccine Sales by Country
5.1.1 Americas Inactivated Influenza Vaccine Sales by Country (2018-2023)
5.1.2 Americas Inactivated Influenza Vaccine Revenue by Country (2018-2023)
5.2 Americas Inactivated Influenza Vaccine Sales by Type
5.3 Americas Inactivated Influenza Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Inactivated Influenza Vaccine Sales by Region
6.1.1 APAC Inactivated Influenza Vaccine Sales by Region (2018-2023)
6.1.2 APAC Inactivated Influenza Vaccine Revenue by Region (2018-2023)
6.2 APAC Inactivated Influenza Vaccine Sales by Type
6.3 APAC Inactivated Influenza Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Inactivated Influenza Vaccine by Country
7.1.1 Europe Inactivated Influenza Vaccine Sales by Country (2018-2023)
7.1.2 Europe Inactivated Influenza Vaccine Revenue by Country (2018-2023)
7.2 Europe Inactivated Influenza Vaccine Sales by Type
7.3 Europe Inactivated Influenza Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Inactivated Influenza Vaccine by Country
8.1.1 Middle East & Africa Inactivated Influenza Vaccine Sales by Country (2018-2023)
8.1.2 Middle East & Africa Inactivated Influenza Vaccine Revenue by Country (2018-2023)
8.2 Middle East & Africa Inactivated Influenza Vaccine Sales by Type
8.3 Middle East & Africa Inactivated Influenza Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Inactivated Influenza Vaccine
10.3 Manufacturing Process Analysis of Inactivated Influenza Vaccine
10.4 Industry Chain Structure of Inactivated Influenza Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Inactivated Influenza Vaccine Distributors
11.3 Inactivated Influenza Vaccine Customer
12 WORLD FORECAST REVIEW FOR INACTIVATED INFLUENZA VACCINE BY GEOGRAPHIC REGION
12.1 Global Inactivated Influenza Vaccine Market Size Forecast by Region
12.1.1 Global Inactivated Influenza Vaccine Forecast by Region (2024-2029)
12.1.2 Global Inactivated Influenza Vaccine Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Inactivated Influenza Vaccine Forecast by Type
12.7 Global Inactivated Influenza Vaccine Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 CSL Limited
13.1.1 CSL Limited Company Information
13.1.2 CSL Limited Inactivated Influenza Vaccine Product Portfolios and Specifications
13.1.3 CSL Limited Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 CSL Limited Main Business Overview
13.1.5 CSL Limited Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Inactivated Influenza Vaccine Product Portfolios and Specifications
13.2.3 GSK Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Sanofi Pasteur
13.3.1 Sanofi Pasteur Company Information
13.3.2 Sanofi Pasteur Inactivated Influenza Vaccine Product Portfolios and Specifications
13.3.3 Sanofi Pasteur Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Sanofi Pasteur Main Business Overview
13.3.5 Sanofi Pasteur Latest Developments
13.4 Viatris
13.4.1 Viatris Company Information
13.4.2 Viatris Inactivated Influenza Vaccine Product Portfolios and Specifications
13.4.3 Viatris Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Viatris Main Business Overview
13.4.5 Viatris Latest Developments
13.5 Hualan Biological
13.5.1 Hualan Biological Company Information
13.5.2 Hualan Biological Inactivated Influenza Vaccine Product Portfolios and Specifications
13.5.3 Hualan Biological Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Hualan Biological Main Business Overview
13.5.5 Hualan Biological Latest Developments
13.6 AstraZeneca
13.6.1 AstraZeneca Company Information
13.6.2 AstraZeneca Inactivated Influenza Vaccine Product Portfolios and Specifications
13.6.3 AstraZeneca Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 AstraZeneca Main Business Overview
13.6.5 AstraZeneca Latest Developments
13.7 Sinovac Biotech
13.7.1 Sinovac Biotech Company Information
13.7.2 Sinovac Biotech Inactivated Influenza Vaccine Product Portfolios and Specifications
13.7.3 Sinovac Biotech Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Sinovac Biotech Main Business Overview
13.7.5 Sinovac Biotech Latest Developments
13.8 Aleph Biomedical
13.8.1 Aleph Biomedical Company Information
13.8.2 Aleph Biomedical Inactivated Influenza Vaccine Product Portfolios and Specifications
13.8.3 Aleph Biomedical Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Aleph Biomedical Main Business Overview
13.8.5 Aleph Biomedical Latest Developments
13.9 Abbott Laboratories
13.9.1 Abbott Laboratories Company Information
13.9.2 Abbott Laboratories Inactivated Influenza Vaccine Product Portfolios and Specifications
13.9.3 Abbott Laboratories Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Abbott Laboratories Main Business Overview
13.9.5 Abbott Laboratories Latest Developments
13.10 Novartis International
13.10.1 Novartis International Company Information
13.10.2 Novartis International Inactivated Influenza Vaccine Product Portfolios and Specifications
13.10.3 Novartis International Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Novartis International Main Business Overview
13.10.5 Novartis International Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Inactivated Influenza Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Inactivated Influenza Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Trivalent Influenza Vaccine
Table 4. Major Players of Quadrivalent Influenza Vaccine
Table 5. Global Inactivated Influenza Vaccine Sales by Type (2018-2023) & (K Units)
Table 6. Global Inactivated Influenza Vaccine Sales Market Share by Type (2018-2023)
Table 7. Global Inactivated Influenza Vaccine Revenue by Type (2018-2023) & ($ million)
Table 8. Global Inactivated Influenza Vaccine Revenue Market Share by Type (2018-2023)
Table 9. Global Inactivated Influenza Vaccine Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Inactivated Influenza Vaccine Sales by Application (2018-2023) & (K Units)
Table 11. Global Inactivated Influenza Vaccine Sales Market Share by Application (2018-2023)
Table 12. Global Inactivated Influenza Vaccine Revenue by Application (2018-2023)
Table 13. Global Inactivated Influenza Vaccine Revenue Market Share by Application (2018-2023)
Table 14. Global Inactivated Influenza Vaccine Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Inactivated Influenza Vaccine Sales by Company (2018-2023) & (K Units)
Table 16. Global Inactivated Influenza Vaccine Sales Market Share by Company (2018-2023)
Table 17. Global Inactivated Influenza Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Inactivated Influenza Vaccine Revenue Market Share by Company (2018-2023)
Table 19. Global Inactivated Influenza Vaccine Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Inactivated Influenza Vaccine Producing Area Distribution and Sales Area
Table 21. Players Inactivated Influenza Vaccine Products Offered
Table 22. Inactivated Influenza Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Inactivated Influenza Vaccine Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Inactivated Influenza Vaccine Sales Market Share Geographic Region (2018-2023)
Table 27. Global Inactivated Influenza Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Inactivated Influenza Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Inactivated Influenza Vaccine Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Inactivated Influenza Vaccine Sales Market Share by Country/Region (2018-2023)
Table 31. Global Inactivated Influenza Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Inactivated Influenza Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Inactivated Influenza Vaccine Sales by Country (2018-2023) & (K Units)
Table 34. Americas Inactivated Influenza Vaccine Sales Market Share by Country (2018-2023)
Table 35. Americas Inactivated Influenza Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Inactivated Influenza Vaccine Revenue Market Share by Country (2018-2023)
Table 37. Americas Inactivated Influenza Vaccine Sales by Type (2018-2023) & (K Units)
Table 38. Americas Inactivated Influenza Vaccine Sales by Application (2018-2023) & (K Units)
Table 39. APAC Inactivated Influenza Vaccine Sales by Region (2018-2023) & (K Units)
Table 40. APAC Inactivated Influenza Vaccine Sales Market Share by Region (2018-2023)
Table 41. APAC Inactivated Influenza Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Inactivated Influenza Vaccine Revenue Market Share by Region (2018-2023)
Table 43. APAC Inactivated Influenza Vaccine Sales by Type (2018-2023) & (K Units)
Table 44. APAC Inactivated Influenza Vaccine Sales by Application (2018-2023) & (K Units)
Table 45. Europe Inactivated Influenza Vaccine Sales by Country (2018-2023) & (K Units)
Table 46. Europe Inactivated Influenza Vaccine Sales Market Share by Country (2018-2023)
Table 47. Europe Inactivated Influenza Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Inactivated Influenza Vaccine Revenue Market Share by Country (2018-2023)
Table 49. Europe Inactivated Influenza Vaccine Sales by Type (2018-2023) & (K Units)
Table 50. Europe Inactivated Influenza Vaccine Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Inactivated Influenza Vaccine Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Inactivated Influenza Vaccine Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Inactivated Influenza Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Inactivated Influenza Vaccine Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Inactivated Influenza Vaccine Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Inactivated Influenza Vaccine Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Inactivated Influenza Vaccine
Table 58. Key Market Challenges & Risks of Inactivated Influenza Vaccine
Table 59. Key Industry Trends of Inactivated Influenza Vaccine
Table 60. Inactivated Influenza Vaccine Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Inactivated Influenza Vaccine Distributors List
Table 63. Inactivated Influenza Vaccine Customer List
Table 64. Global Inactivated Influenza Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Inactivated Influenza Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Inactivated Influenza Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Inactivated Influenza Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Inactivated Influenza Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Inactivated Influenza Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Inactivated Influenza Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Inactivated Influenza Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Inactivated Influenza Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Inactivated Influenza Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Inactivated Influenza Vaccine Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Inactivated Influenza Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Inactivated Influenza Vaccine Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Inactivated Influenza Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. CSL Limited Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. CSL Limited Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 80. CSL Limited Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. CSL Limited Main Business
Table 82. CSL Limited Latest Developments
Table 83. GSK Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. GSK Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 85. GSK Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. GSK Main Business
Table 87. GSK Latest Developments
Table 88. Sanofi Pasteur Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Pasteur Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 90. Sanofi Pasteur Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Sanofi Pasteur Main Business
Table 92. Sanofi Pasteur Latest Developments
Table 93. Viatris Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. Viatris Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 95. Viatris Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Viatris Main Business
Table 97. Viatris Latest Developments
Table 98. Hualan Biological Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Hualan Biological Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 100. Hualan Biological Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Hualan Biological Main Business
Table 102. Hualan Biological Latest Developments
Table 103. AstraZeneca Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. AstraZeneca Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 105. AstraZeneca Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. AstraZeneca Main Business
Table 107. AstraZeneca Latest Developments
Table 108. Sinovac Biotech Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Sinovac Biotech Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 110. Sinovac Biotech Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Sinovac Biotech Main Business
Table 112. Sinovac Biotech Latest Developments
Table 113. Aleph Biomedical Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Aleph Biomedical Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 115. Aleph Biomedical Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Aleph Biomedical Main Business
Table 117. Aleph Biomedical Latest Developments
Table 118. Abbott Laboratories Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. Abbott Laboratories Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 120. Abbott Laboratories Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Abbott Laboratories Main Business
Table 122. Abbott Laboratories Latest Developments
Table 123. Novartis International Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Novartis International Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 125. Novartis International Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Novartis International Main Business
Table 127. Novartis International Latest Developments
Table 1. Inactivated Influenza Vaccine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Inactivated Influenza Vaccine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Trivalent Influenza Vaccine
Table 4. Major Players of Quadrivalent Influenza Vaccine
Table 5. Global Inactivated Influenza Vaccine Sales by Type (2018-2023) & (K Units)
Table 6. Global Inactivated Influenza Vaccine Sales Market Share by Type (2018-2023)
Table 7. Global Inactivated Influenza Vaccine Revenue by Type (2018-2023) & ($ million)
Table 8. Global Inactivated Influenza Vaccine Revenue Market Share by Type (2018-2023)
Table 9. Global Inactivated Influenza Vaccine Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Inactivated Influenza Vaccine Sales by Application (2018-2023) & (K Units)
Table 11. Global Inactivated Influenza Vaccine Sales Market Share by Application (2018-2023)
Table 12. Global Inactivated Influenza Vaccine Revenue by Application (2018-2023)
Table 13. Global Inactivated Influenza Vaccine Revenue Market Share by Application (2018-2023)
Table 14. Global Inactivated Influenza Vaccine Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Inactivated Influenza Vaccine Sales by Company (2018-2023) & (K Units)
Table 16. Global Inactivated Influenza Vaccine Sales Market Share by Company (2018-2023)
Table 17. Global Inactivated Influenza Vaccine Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Inactivated Influenza Vaccine Revenue Market Share by Company (2018-2023)
Table 19. Global Inactivated Influenza Vaccine Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Inactivated Influenza Vaccine Producing Area Distribution and Sales Area
Table 21. Players Inactivated Influenza Vaccine Products Offered
Table 22. Inactivated Influenza Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Inactivated Influenza Vaccine Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Inactivated Influenza Vaccine Sales Market Share Geographic Region (2018-2023)
Table 27. Global Inactivated Influenza Vaccine Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Inactivated Influenza Vaccine Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Inactivated Influenza Vaccine Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Inactivated Influenza Vaccine Sales Market Share by Country/Region (2018-2023)
Table 31. Global Inactivated Influenza Vaccine Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Inactivated Influenza Vaccine Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Inactivated Influenza Vaccine Sales by Country (2018-2023) & (K Units)
Table 34. Americas Inactivated Influenza Vaccine Sales Market Share by Country (2018-2023)
Table 35. Americas Inactivated Influenza Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Inactivated Influenza Vaccine Revenue Market Share by Country (2018-2023)
Table 37. Americas Inactivated Influenza Vaccine Sales by Type (2018-2023) & (K Units)
Table 38. Americas Inactivated Influenza Vaccine Sales by Application (2018-2023) & (K Units)
Table 39. APAC Inactivated Influenza Vaccine Sales by Region (2018-2023) & (K Units)
Table 40. APAC Inactivated Influenza Vaccine Sales Market Share by Region (2018-2023)
Table 41. APAC Inactivated Influenza Vaccine Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Inactivated Influenza Vaccine Revenue Market Share by Region (2018-2023)
Table 43. APAC Inactivated Influenza Vaccine Sales by Type (2018-2023) & (K Units)
Table 44. APAC Inactivated Influenza Vaccine Sales by Application (2018-2023) & (K Units)
Table 45. Europe Inactivated Influenza Vaccine Sales by Country (2018-2023) & (K Units)
Table 46. Europe Inactivated Influenza Vaccine Sales Market Share by Country (2018-2023)
Table 47. Europe Inactivated Influenza Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Inactivated Influenza Vaccine Revenue Market Share by Country (2018-2023)
Table 49. Europe Inactivated Influenza Vaccine Sales by Type (2018-2023) & (K Units)
Table 50. Europe Inactivated Influenza Vaccine Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Inactivated Influenza Vaccine Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Inactivated Influenza Vaccine Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Inactivated Influenza Vaccine Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Inactivated Influenza Vaccine Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Inactivated Influenza Vaccine Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Inactivated Influenza Vaccine Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Inactivated Influenza Vaccine
Table 58. Key Market Challenges & Risks of Inactivated Influenza Vaccine
Table 59. Key Industry Trends of Inactivated Influenza Vaccine
Table 60. Inactivated Influenza Vaccine Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Inactivated Influenza Vaccine Distributors List
Table 63. Inactivated Influenza Vaccine Customer List
Table 64. Global Inactivated Influenza Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Inactivated Influenza Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Inactivated Influenza Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Inactivated Influenza Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Inactivated Influenza Vaccine Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Inactivated Influenza Vaccine Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Inactivated Influenza Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Inactivated Influenza Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Inactivated Influenza Vaccine Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Inactivated Influenza Vaccine Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Inactivated Influenza Vaccine Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Inactivated Influenza Vaccine Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Inactivated Influenza Vaccine Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Inactivated Influenza Vaccine Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. CSL Limited Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. CSL Limited Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 80. CSL Limited Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. CSL Limited Main Business
Table 82. CSL Limited Latest Developments
Table 83. GSK Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. GSK Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 85. GSK Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. GSK Main Business
Table 87. GSK Latest Developments
Table 88. Sanofi Pasteur Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Pasteur Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 90. Sanofi Pasteur Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Sanofi Pasteur Main Business
Table 92. Sanofi Pasteur Latest Developments
Table 93. Viatris Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. Viatris Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 95. Viatris Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Viatris Main Business
Table 97. Viatris Latest Developments
Table 98. Hualan Biological Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Hualan Biological Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 100. Hualan Biological Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Hualan Biological Main Business
Table 102. Hualan Biological Latest Developments
Table 103. AstraZeneca Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. AstraZeneca Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 105. AstraZeneca Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. AstraZeneca Main Business
Table 107. AstraZeneca Latest Developments
Table 108. Sinovac Biotech Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Sinovac Biotech Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 110. Sinovac Biotech Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Sinovac Biotech Main Business
Table 112. Sinovac Biotech Latest Developments
Table 113. Aleph Biomedical Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Aleph Biomedical Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 115. Aleph Biomedical Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Aleph Biomedical Main Business
Table 117. Aleph Biomedical Latest Developments
Table 118. Abbott Laboratories Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. Abbott Laboratories Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 120. Abbott Laboratories Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Abbott Laboratories Main Business
Table 122. Abbott Laboratories Latest Developments
Table 123. Novartis International Basic Information, Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Novartis International Inactivated Influenza Vaccine Product Portfolios and Specifications
Table 125. Novartis International Inactivated Influenza Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Novartis International Main Business
Table 127. Novartis International Latest Developments
LIST OF FIGURES
Figure 1. Picture of Inactivated Influenza Vaccine
Figure 2. Inactivated Influenza Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Inactivated Influenza Vaccine Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Inactivated Influenza Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Inactivated Influenza Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Trivalent Influenza Vaccine
Figure 10. Product Picture of Quadrivalent Influenza Vaccine
Figure 11. Global Inactivated Influenza Vaccine Sales Market Share by Type in 2022
Figure 12. Global Inactivated Influenza Vaccine Revenue Market Share by Type (2018-2023)
Figure 13. Inactivated Influenza Vaccine Consumed in Children
Figure 14. Global Inactivated Influenza Vaccine Market: Children (2018-2023) & (K Units)
Figure 15. Inactivated Influenza Vaccine Consumed in Adolescence
Figure 16. Global Inactivated Influenza Vaccine Market: Adolescence (2018-2023) & (K Units)
Figure 17. Inactivated Influenza Vaccine Consumed in Adults
Figure 18. Global Inactivated Influenza Vaccine Market: Adults (2018-2023) & (K Units)
Figure 19. Inactivated Influenza Vaccine Consumed in Elderly
Figure 20. Global Inactivated Influenza Vaccine Market: Elderly (2018-2023) & (K Units)
Figure 21. Global Inactivated Influenza Vaccine Sales Market Share by Application (2022)
Figure 22. Global Inactivated Influenza Vaccine Revenue Market Share by Application in 2022
Figure 23. Inactivated Influenza Vaccine Sales Market by Company in 2022 (K Units)
Figure 24. Global Inactivated Influenza Vaccine Sales Market Share by Company in 2022
Figure 25. Inactivated Influenza Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Inactivated Influenza Vaccine Revenue Market Share by Company in 2022
Figure 27. Global Inactivated Influenza Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Inactivated Influenza Vaccine Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Inactivated Influenza Vaccine Sales 2018-2023 (K Units)
Figure 30. Americas Inactivated Influenza Vaccine Revenue 2018-2023 ($ Millions)
Figure 31. APAC Inactivated Influenza Vaccine Sales 2018-2023 (K Units)
Figure 32. APAC Inactivated Influenza Vaccine Revenue 2018-2023 ($ Millions)
Figure 33. Europe Inactivated Influenza Vaccine Sales 2018-2023 (K Units)
Figure 34. Europe Inactivated Influenza Vaccine Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Inactivated Influenza Vaccine Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Inactivated Influenza Vaccine Revenue 2018-2023 ($ Millions)
Figure 37. Americas Inactivated Influenza Vaccine Sales Market Share by Country in 2022
Figure 38. Americas Inactivated Influenza Vaccine Revenue Market Share by Country in 2022
Figure 39. Americas Inactivated Influenza Vaccine Sales Market Share by Type (2018-2023)
Figure 40. Americas Inactivated Influenza Vaccine Sales Market Share by Application (2018-2023)
Figure 41. United States Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Inactivated Influenza Vaccine Sales Market Share by Region in 2022
Figure 46. APAC Inactivated Influenza Vaccine Revenue Market Share by Regions in 2022
Figure 47. APAC Inactivated Influenza Vaccine Sales Market Share by Type (2018-2023)
Figure 48. APAC Inactivated Influenza Vaccine Sales Market Share by Application (2018-2023)
Figure 49. China Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Inactivated Influenza Vaccine Sales Market Share by Country in 2022
Figure 57. Europe Inactivated Influenza Vaccine Revenue Market Share by Country in 2022
Figure 58. Europe Inactivated Influenza Vaccine Sales Market Share by Type (2018-2023)
Figure 59. Europe Inactivated Influenza Vaccine Sales Market Share by Application (2018-2023)
Figure 60. Germany Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Inactivated Influenza Vaccine Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Inactivated Influenza Vaccine Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Inactivated Influenza Vaccine Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Inactivated Influenza Vaccine Sales Market Share by Application (2018-2023)
Figure 69. Egypt Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Inactivated Influenza Vaccine in 2022
Figure 75. Manufacturing Process Analysis of Inactivated Influenza Vaccine
Figure 76. Industry Chain Structure of Inactivated Influenza Vaccine
Figure 77. Channels of Distribution
Figure 78. Global Inactivated Influenza Vaccine Sales Market Forecast by Region (2024-2029)
Figure 79. Global Inactivated Influenza Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Inactivated Influenza Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Inactivated Influenza Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Inactivated Influenza Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Inactivated Influenza Vaccine Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Inactivated Influenza Vaccine
Figure 2. Inactivated Influenza Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Inactivated Influenza Vaccine Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Inactivated Influenza Vaccine Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Inactivated Influenza Vaccine Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Trivalent Influenza Vaccine
Figure 10. Product Picture of Quadrivalent Influenza Vaccine
Figure 11. Global Inactivated Influenza Vaccine Sales Market Share by Type in 2022
Figure 12. Global Inactivated Influenza Vaccine Revenue Market Share by Type (2018-2023)
Figure 13. Inactivated Influenza Vaccine Consumed in Children
Figure 14. Global Inactivated Influenza Vaccine Market: Children (2018-2023) & (K Units)
Figure 15. Inactivated Influenza Vaccine Consumed in Adolescence
Figure 16. Global Inactivated Influenza Vaccine Market: Adolescence (2018-2023) & (K Units)
Figure 17. Inactivated Influenza Vaccine Consumed in Adults
Figure 18. Global Inactivated Influenza Vaccine Market: Adults (2018-2023) & (K Units)
Figure 19. Inactivated Influenza Vaccine Consumed in Elderly
Figure 20. Global Inactivated Influenza Vaccine Market: Elderly (2018-2023) & (K Units)
Figure 21. Global Inactivated Influenza Vaccine Sales Market Share by Application (2022)
Figure 22. Global Inactivated Influenza Vaccine Revenue Market Share by Application in 2022
Figure 23. Inactivated Influenza Vaccine Sales Market by Company in 2022 (K Units)
Figure 24. Global Inactivated Influenza Vaccine Sales Market Share by Company in 2022
Figure 25. Inactivated Influenza Vaccine Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Inactivated Influenza Vaccine Revenue Market Share by Company in 2022
Figure 27. Global Inactivated Influenza Vaccine Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Inactivated Influenza Vaccine Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Inactivated Influenza Vaccine Sales 2018-2023 (K Units)
Figure 30. Americas Inactivated Influenza Vaccine Revenue 2018-2023 ($ Millions)
Figure 31. APAC Inactivated Influenza Vaccine Sales 2018-2023 (K Units)
Figure 32. APAC Inactivated Influenza Vaccine Revenue 2018-2023 ($ Millions)
Figure 33. Europe Inactivated Influenza Vaccine Sales 2018-2023 (K Units)
Figure 34. Europe Inactivated Influenza Vaccine Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Inactivated Influenza Vaccine Sales 2018-2023 (K Units)
Figure 36. Middle East & Africa Inactivated Influenza Vaccine Revenue 2018-2023 ($ Millions)
Figure 37. Americas Inactivated Influenza Vaccine Sales Market Share by Country in 2022
Figure 38. Americas Inactivated Influenza Vaccine Revenue Market Share by Country in 2022
Figure 39. Americas Inactivated Influenza Vaccine Sales Market Share by Type (2018-2023)
Figure 40. Americas Inactivated Influenza Vaccine Sales Market Share by Application (2018-2023)
Figure 41. United States Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Inactivated Influenza Vaccine Sales Market Share by Region in 2022
Figure 46. APAC Inactivated Influenza Vaccine Revenue Market Share by Regions in 2022
Figure 47. APAC Inactivated Influenza Vaccine Sales Market Share by Type (2018-2023)
Figure 48. APAC Inactivated Influenza Vaccine Sales Market Share by Application (2018-2023)
Figure 49. China Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Inactivated Influenza Vaccine Sales Market Share by Country in 2022
Figure 57. Europe Inactivated Influenza Vaccine Revenue Market Share by Country in 2022
Figure 58. Europe Inactivated Influenza Vaccine Sales Market Share by Type (2018-2023)
Figure 59. Europe Inactivated Influenza Vaccine Sales Market Share by Application (2018-2023)
Figure 60. Germany Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Inactivated Influenza Vaccine Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Inactivated Influenza Vaccine Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Inactivated Influenza Vaccine Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Inactivated Influenza Vaccine Sales Market Share by Application (2018-2023)
Figure 69. Egypt Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Inactivated Influenza Vaccine Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Inactivated Influenza Vaccine in 2022
Figure 75. Manufacturing Process Analysis of Inactivated Influenza Vaccine
Figure 76. Industry Chain Structure of Inactivated Influenza Vaccine
Figure 77. Channels of Distribution
Figure 78. Global Inactivated Influenza Vaccine Sales Market Forecast by Region (2024-2029)
Figure 79. Global Inactivated Influenza Vaccine Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Inactivated Influenza Vaccine Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Inactivated Influenza Vaccine Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Inactivated Influenza Vaccine Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Inactivated Influenza Vaccine Revenue Market Share Forecast by Application (2024-2029)
